Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 4, 1997, Pages 142-150

  Endrenyi, L ^a   Tothfalusi, L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bioequivalence; Long half life; Simulation; Truncated AUC; Variation of AUC

Indexed keywords

DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; METHODOLOGY; PHARMACOKINETICS; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; AREA UNDER CURVE; COMPUTER SIMULATION; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; KINETICS; LINEAR MODELS; MODELS, BIOLOGICAL; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY;

EID: 0030940823     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bois FY, Tozer TN, Hauck WW, Chen ML, Patnaik R, Williams RL 1994 Bioequivalence: performance of several measures of extent of absorption. Pharm Res 11: 715-722
2. Cartwright AC, Gundert-Remy W, Rauws G, McGilveray I, Salmonson T, Walters S 1991 International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing requirements and standards. Drug Inform J 25: 471-482
3. Chen M-L 1992 An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm Res 9: 1380-1385
4. Endrenyi L, Tothfalusi L, Zha J 1995 Metrics assessing absorption rates: principles, and determination of bioequivalence in the steady state. In: Blume HH, Midha KK (eds) Bio International 2: Bioavailability, Bioequivalence and Pharmacokinetic Studies. Medpharm, Stuttgart, pp 77-85
5. Endrenyi L, Tothfalusi L, Lalonde RL, Gaudreault J 1996 Partial AUC is effective for assessing the bioequivalence of drugs with long half-lives. Clin Pharmacol Ther 59: 152
6. Lovering EJ, McGilveray IJ, McMillan I, Tostowaryk W 1975 Comparative bioavailabilities from truncated blood level curves. J Pharm Sci 64: 1521-1524
7. Martinez MN, Jackson AJ 1991 Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). Pharm Res 8: 512-517
8. McGilveray IJ, Midha KK, Loo JCK, Cooper JK 1978 The bioavailability of commercial metronidazole formulations. Int J Clin Pharmacol Biopharm 16: 110-115
9. Midha KK, Hubbard JW, Rawson MJ 1996 Retrospective evaluation of relative extent of absorption by the use of partial areas under plasma concentration versus time curves in bioequivalence studies on conventional release products. Eur J Pharm Sci 4: 133-138
10. Midha KK, Hubbard JW, Rawson M, Gavalas L 1994 The application of partial areas in assessment of rate and extent of absorption in bioequivalence studies of conventional release products: experimental evidence. Eur J Pharm Sci 2: 351-363
11. Press WH, Teukolsky SA, Vetterling VT, Flannery SA 1992 Numerical Recipes in Fortran. Cambridge University Press, Cambridge
12. Romero AJ, Bon C, Johson E, Rosenbaum SE, Rhodes CT 1990 Use and limitations of the truncated area under curve in bioequivalence testing. Clin Res Pract Drug Regul Affairs 8: 123-151
13. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm 15: 657-680
14. max/AUC is an effective metric in investigations of bioequivalence. Pharm Res 12: 937-942
15. 0-72 in bioequivalence assessment for drugs with a long half-life. Pharm Res 13: S477